CN104706675A - Composition for treating osteoarthritis - Google Patents
Composition for treating osteoarthritis Download PDFInfo
- Publication number
- CN104706675A CN104706675A CN201310688816.3A CN201310688816A CN104706675A CN 104706675 A CN104706675 A CN 104706675A CN 201310688816 A CN201310688816 A CN 201310688816A CN 104706675 A CN104706675 A CN 104706675A
- Authority
- CN
- China
- Prior art keywords
- compositions
- fat
- pluripotent cell
- cell
- lower group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Abstract
The invention provides a composition for treating animal osteoarthritis, and specifically, provides a biological product for treating animal osteoarthritis and a preparation prepared by the product. The product is prepared by combining a fat pluripotent cell component and a scaffold material with other components, and has the characteristics of quick acting, good treatment effect, less dosage and the like.
Description
Technical field
The present invention relates to medical science and biomedical engineering field, be specifically related to a kind of biological product for the treatment of osteoarthritis and preparation method thereof.
Background technology
Osteoarthritis is a kind of chronic joint disease being feature with the degeneration of articular cartilage, destruction and hyperosteogeny, and sickness rate is high, and very common in aging population, in the crowd of more than 60 years old, prevalence can reach 50%, then reaches 80% in the crowd of more than 75 years old.The arthralgia of Human Osteoarthritis often makes patient be difficult to stand, and after morbidity, disability rate is high.The medicine of existing treatment osteoarthritis can delay the course of disease to a certain extent, improve patients symptomatic, reduction of patient pain, but can not reverse pathological process, can not effect a radical cure osteoarthritis, and most of drug side effect is obvious.And surgical operation therapy is mainly through arthroscope (sight glass), open surgery or prosthetic replacement, although energy respite pain, long-range effect (about 10 years) is unsatisfactory.The cell therapies such as stem cell are the new methods being hopeful thoroughly to solve osteoarthritis treatment at present most.
Often there is cartilage defect in osteoarthritis, but self repair ability of cartilage is limited, usually can using the most important evaluation index of repair of cartilage as osteoarthritis treatment.Nearly ten years, cellular replacement therapy osteoarthritis has large quantity research report.Stem cell can play immunoregulation effect, inflammatory reaction regulating action after injecting osteoarthritic joint, reduces pain; Secretion anti-apoptosis factor and the fibrosis factor suppress disease progression; The factors such as secretion TGF-β, BMP-4, promote endogenous retinal stem cells repair of cartilage; Chondrocyte can also be divided into help to repair cartilage.
Except the mankind, most animals also easily suffers from osteoarthritis, and particularly common animal is as Canis animals, equine species etc., and because quantity of motion is large, owner raises the reasons such as improper, the sickness rate comparatively mankind is even higher.As, in the one-tenth dog of the large-scale dog of part, the sickness rate of osteoarthritis can reach 20%; And the sickness rate of the one-tenth dog of more than 10 years old can up to 95%.For in the arthritic clinical treatment of animal bone, mostly only use anti-inflammatory agent, therapeutic effect is very limited.
The stem-cell therapy research of current osteoarthritis adopts the mescenchymal stem cell of derived from bone marrow mostly, fat pluripotent cell treatment osteoarthritis is existing lot of documents report also, preclinical study and clinical studies show mesenchymal stem cells MSCs and fatty pluripotent stem cell all likely improve the state of an illness, and have the report increasing cartilage content.Mesenchymal stem cells MSCs obtains and need to puncture bone marrow, causes comparatively major injury to donor, Comparatively speaking obtains pluripotent cell from fat and has more advantage, 1) draw materials little to body injury; 2) in fat, the pluripotent cell content of tool CFU-F Forming ability, higher than 1%, and is less than 0.001% in bone marrow; 3) adipose-derived abundant, the content of pluripotent cell is many; 4) comparatively mesenchymal stem cells MSCs is strong for adipose-derived cells multiplication capacity.Therefore fatty pluripotent stem cell treatment osteoarthritis has more advantage.
Lipid substrate vascular components (is called " Stromal vascular fraction ", or SVF) containing fat pluripotent cell, and containing multiple other types cell, enzymic digestion method can be adopted to obtain from fatty tissue, can be passed through extraction purification and isolate out fatty pluripotent stem cell.Stromal vascular fraction also has therapeutic effect to osteoarthritis treatment, and stromal vascular fraction transplants 1-3 hour from being separated to, and cost is low, can also reduce the risk in cell culture, but the fat pluripotent cell content contained is few.Pluripotent cell simultaneously containing CD34+CD31-and CD34+CD31+ in stromal vascular fraction, has stronger promotion revascularization ability, and the fat pluripotent cell CD34+ after cultivating expresses minimizing or disappears.But this area still lacks a kind of optimizing components, and impurity content is few, active constituent content high the liquid formulation for the treatment of osteoarthritis.
Summary of the invention
The object of this invention is to provide a kind of optimizing components, impurity content is few, the fluid composition of the treatment osteoarthritis that active constituent content is high.
A first aspect of the present invention, provide one and treat the arthritic compositions of animal bone, described compositions comprises following component:
A. fat pluripotent cell component; And/or
Cartilage precursor cells component;
B. timbering material; With
C. pharmaceutically acceptable carrier.
In another preference, described compositions is fluid composition.
In another preference, described compositions is injection.
In another preference, described pharmaceutically acceptable carrier is injection carrier.
In another preference, described osteoarthritis is selected from lower group: knee osteoarthritis, hipbone arthritis, anklebone arthritis.
In another preference, described fat pluripotent cell component is autologous fat pluripotent cell component or allosome fat pluripotent cell component.
In another preference, described fat pluripotent cell component is selected from lower group: the fat pluripotent cell of purification, the fat pluripotent cell through cultivation amplification from stromal vascular fraction, or its combination.
In another preference, the described fat pluripotent cell through cultivating amplification be serum-free medium or containing the culture medium of serum in carry out increasing.
In another preference, described fat pluripotent cell component is the standby or cryopreservation resuscitation of immediate system.
In another preference, except fat pluripotent cell, described fat pluripotent cell component also can containing the cell being selected from lower group: adipose cell, endotheliocyte, smooth muscle cell, pericyte, fibroblast, mastocyte, neurocyte, Preadipocyte, lymphocyte, blood cell, stromal cell, macrophage, or its combination.
In another preference, in described fat pluripotent cell component, fat pluripotent cell quantity accounts for 0.5 ~ 100% of total cell quantity, is preferably 1 ~ 100%, is more preferably 10 ~ 100%.
In another preference, described fat pluripotent cell component is autologous or allochthonous.
In another preference, described fat pluripotent cell component has cartilage differentiation potential.
In another preference, also containing cytokine in described fat pluripotent cell component.
In another preference, described cartilage precursor cells component is autologous or allochthonous.
In another preference, described cartilage precursor cells component has cartilage differentiation potential.
In another preference, also containing cytokine in described cartilage precursor cells component.
In another preference, described cytokine is selected from lower group: TGF-β, PDGF, VEGF, IL-1, IL-6, TNF, IRAP, CTGF, EGF, IGF, BFGF, or its combination.
In another preference, described fat pluripotent cell and/or cartilage precursor cells total concentration is in the composition 1 × 10
3-5 × 10
8/ mL is preferably 1 × 10
4-1 × 10
8/ mL is more preferably 1 × 10
5-1 × 10
7/ mL.
In another preference, described fat pluripotent cell component is CD45-CD235a-CD31-CD34+ cell, and/or the fat pluripotent cell component of CD45-CD13+CD36+CD73+ cell enrichment.
In another preference, described CD45-CD235a-CD31-CD34+ cell and/or CD45-CD13+CD36+CD73+ cell enrichment refer to that the content of described CD45-CD235a-CD31-CD34+ cell and/or CD45-CD13+CD36+CD73+ cell accounts for the 15-100% of cell total amount in component.
In another preference, described " CD45-CD235a-CD31-CD34+ " cell refers to containing CD34 cytokine not containing CD45, CD235a and CD31 cytokine.
In another preference, described compositions also comprises one or more compositions being selected from lower group:
Optional is rich in hematoblastic blood plasma (PRP) and/or fat stem cell culture supernatant;
Vitamin B12;
Vitamin C; With
Anti-inflammatory drug.
In another preference, the described hematoblastic blood plasma that is rich in is existing system or prefabricated.
In another preference, the described hematoblastic blood plasma that is rich in is autologous or allosome.
In another preference, described fat stem cell culture supernatant is existing system or prefabricated.
In another preference, described fat stem cell culture supernatant is autologous or allosome.
In another preference, the described hematoblastic blood plasma (PRP) that is rich in is selected from lower group: the PRP after activation, does not activate PRP liquid, PRP gel, or its combination.
In another preference, described in be rich in hematoblastic blood plasma, PC scope is 0.5 × 10
6-1.5 × 10
10/ mL, and in described blood plasma, leukocyte and erythrocytic total concentration are≤1 × 10
6/ mL.
In another preference, described in be rich in hematoblastic blood plasma, PC scope is 5 × 10
7-5 × 10
8/ mL.
In another preference, containing cytokine in described fat stem cell culture supernatant.
In another preference, containing the cytokine being selected from lower group: TGF-β, HGF, TGF-1, PDGF, VEGF, EGF, IGF, BFGF in described fat stem cell culture supernatant, or its combination.
In another preference, described fat stem cell culture supernatant is the fat stem cell culture supernatant of deactivation.
In another preference, not containing cell in described fat stem cell culture supernatant.
In another preference, described timbering material is selected from lower group: hyaluronic acid sodium, collagen protein, polysaccharide, or its combination.
In another preference, described polysaccharide is selected from lower group: hyaluronic acid, derivatives of hyaluronic acids, dextran, alginic acid, chitin, or its combination.
In another preference, described timbering material is the combination of hyaluronic acid sodium and collagen protein.
In another preference, described hyaluronic acid sodium and collagen protein first carry out premixing.
In another preference, described anti-inflammatory drug is selected from lower group: glucocorticoid AID, meloxicam, Luo Beikao former times, or its combination.
In another preference, described fat pluripotent cell component and/or cartilage precursor cells component gross weight ratio is in the composition 5-95 weight portion, with the total weight of compositions; And/or
Described timbering material weight ratio is in the composition 5-95 weight portion, is preferably 10-90 weight portion, with the total weight of compositions.
In another preference, in described compositions, the weight ratio of described vitamin B12 is 0.001-10 weight portion, is preferably 0.01-5 weight portion, with the total weight of compositions.
In another preference, in described compositions, the weight ratio of described anti-inflammatory drug is 10-95 weight portion, with the total weight of compositions.
In another preference, in described compositions, described in be rich in hematoblastic blood plasma and/or fat stem cell culture supernatant gross weight than being 0.1-10 weight portion, with the total weight of compositions.
In another preference, in described compositions, described ascorbic weight ratio is 0.001-10 weight portion, is preferably 0.01-5 weight portion, with the total weight of compositions.
In another preference, described animal is selected from lower group: primate, Canis animals, equine species, rabbit section animal.
In another preference, described animal non-human.
A second aspect of the present invention, provide a kind of method for making of compositions as described in the first aspect of the invention, described method comprises step: each component mixed, make compositions.
A third aspect of the present invention, provides one and is used for the treatment of the arthritic preparation of animal bone, and described preparation comprises compositions as described in the first aspect of the invention as effective ingredient.
In another preference, described preparation is injection.
In another preference, described preparation is used for injecting the diseased joints of the object needed.
In another preference, described injection is intra-articular injection.
In another preference, in described preparation,
The concentration of described fat pluripotent cell is 10
4-10
8/ mL;
Hematoblastic concentration is 5 × 10
7-5 × 10
8/ mL;
Leukocytic concentration is≤5 × 10
5mL;
Erythrocytic concentration is≤5 × 10
5mL; And
The volume of described preparation is 0.1-15mL; And
The somatomedin being selected from lower group is also comprised: TGF-β, PDGF, VEGF, IL-1, IL-6, TNF, IRAP, CTGF, EGF, IGF, BFGF in described blood plasma, or its combination; And/or
The somatomedin being selected from lower group is also comprised: TGF-β, HGF, IL-10, TGF-1, PDGF, VEGF, EGF, IGF, BFGF in described fat stem cell culture supernatant, or its combination; And/or
Also cytokine is comprised in described fat pluripotent cell component and/or described cartilage precursor cells component, and described cytokine is selected from lower group: TGF-β, TIMPs, VEGF, HGF, PGE2, IGF-1, MIP-1a, IL-6, IDO, GM-CSF, IL-1RA, IL-12p40, IL-10, IL-13, or its combination; And/or
The surface marker that described fat pluripotent cell component is expressed is selected from lower group: CD90, CD34, CD10, CD36, CDCD45, CD105, CD29, CD44, CD49b, CD49e, CD58, HLA-ABC, CD73, CD13, CD63, CD166, CD31, CD106, CD71, or its combination.
In another preference, the volume of described preparation is 0.5-5ml.
In another preference, the volume of described preparation is 0.1-1mL.
In another preference, the volume of described preparation is 2-15mL.
A fourth aspect of the present invention, provides one and treats the arthritic agent combination of animal bone or test kit, comprises the reagent of description and lower group:
A. fat pluripotent cell component; And/or
Cartilage precursor cells component;
B. timbering material;
And describe operational version in described description;
Preferably, one or more components being selected from lower group are also comprised in described test kit: be rich in hematoblastic blood plasma (PRP), fat stem cell culture supernatant, vitamin B12, vitamin C; And anti-inflammatory drug.
In another preference, described operational version comprises: after each component mixing, for treating the object of suffering from osteoarthritis.
In another preference, described object is non-human animal.
Present invention also offers one and treat the arthritic method of animal bone, described method comprises: the compositions as described in the first aspect of the invention treatment target being used to effective dose, or treatment target is used to the preparation as described in third aspect present invention of effective dose, or the agent combination as described in fourth aspect present invention or the test kit of effective dose are used to treatment target.
Should be understood that within the scope of the present invention, above-mentioned each technical characteristic of the present invention and can combining mutually between specifically described each technical characteristic in below (eg embodiment), thus form new or preferred technical scheme.As space is limited, tiredly no longer one by one to state at this.
Accompanying drawing explanation
Fig. 1 treats the contrast figure that articular cartilage repairs situation in the embodiment of the present invention 2.
Detailed description of the invention
The present inventor is through long-term and deep research, be surprised to find that, adopt being rich in hematoblastic blood plasma bound fat pluripotent cell and other effective ingredient of separation and purification and make biological product conposition to osteoarthritis and treat, obtaining beyond thought therapeutic effect.And when described biological product are made into or be used as joint injection agent, only need inject a small amount of liquid, extraordinary therapeutic effect can be reached.Based on above-mentioned discovery, inventor completes the present invention.
Osteoarthritis
Osteoarthritis is a kind of chronic joint diseases, and its main change is the degeneration of articular cartilage face and insecondary hyperosteogeny, show arthralgia and activity dumb, x-ray performance joint space narrows, subchondral bone matter is fine and close, and bone trabecula ruptures, and has sclerosis and cystis degeneration; Joint margins has lip sample hypertrophy; Later stage epiphysis distortion, articular surface is uneven; Intraarticular cartilage peels off, and sclerotin is cracked enters joint, forms articular mobile corpus.
In the present invention, described osteoarthritis can be optionally from the osteoarthritis of lower group: knee osteoarthritis, spinal osteoarthritis, hipbone arthritis, ankle arthritis or its combination.Osteoarthritis of the present invention is preferably knee osteoarthritis and hipbone arthritis.
Fat
Fat is the Excellent sources of shaping and antidotal therapy, and fatty tissue material can derive from the positions such as waist, buttocks, abdominal part, thigh, upper arm.Those skilled in the art can adopt general technical method to obtain fatty tissue, include, but is not limited to the method such as suction, operation separation.
In the present invention, fatty tissue or fatty raw material are not particularly limited, and can be the fatty tissuees at any position deriving from animal or human, the fatty tissue of preferred people.Preferably, fatty tissue can be periarticular fatty tissue.
Stromal vascular fraction
Stromal vascular fraction contains fat pluripotent cell, and containing multiple other types cell, is adopt enzymic digestion method to obtain from fatty tissue the earliest, can be passed through extraction purification and isolate out fatty pluripotent stem cell.Stromal vascular fraction also has certain therapeutic effect to osteoarthritis treatment, and stromal vascular fraction only needs 1-2 hour from being separated to transplanting, and low price, the risk in cell culture can also be reduced.Pluripotent cell simultaneously containing CD34+CD31-and CD34+CD31+ in stromal vascular fraction, has stronger promotion revascularization ability, has and significantly promotes the effect that body is repaired.
Be rich in hematoblastic blood plasma (PRP)
PRP can secrete multiple promotion cartilage and recover cytokine, but also studies have reported that it produces counter productive to repair of cartilage.In treatment osteoarthritis, the effect of PRP remains in dispute.
At present, it is huge that PRP prepares diversity, and contained mononuclear cell amount is from 10
6/ milliliter is to 10
10/ milliliter, lacks at present and reports the research of its optimum content scope.
Present invention employs to be separated and remove leukocyte and be erythrocyticly rich in hematoblastic blood plasma, unexpectedly obtain better therapeutic effect.Preferably, in the PRP that the present invention adopts, hematoblastic concentration is 5 × 10
7-5 × 10
8/ mL, white blood cell concentration is≤5 × 10
5mL, erythrocytic concentration is≤5 × 10
5mL.
In the present invention, also comprise the somatomedin being selected from lower group in preferred described blood plasma: TGF-β, PDGF, VEGF, IL-1, IL-6, TNF, IRAP, CTGF, EGF, IGF, BFGF, or its combination.
In the present invention, the described hematoblastic blood plasma that is rich in can be prefabricated or existing system, e.g., can extract and purification in treatment subject before the treatment or in treatment.
Fat stem cell culture supernatant
In compositions of the present invention, preferably also can add fat stem cell culture supernatant, for providing cytokine.Wherein, containing the cytokine being selected from lower group: TGF-β, HGF, TGF-1, PDGF, VEGF, EGF, IGF, BFGF in a kind of preferred described fat stem cell culture supernatant, or its combination.
In another preference, described fat stem cell culture supernatant is the fat stem cell culture supernatant of deactivation.
In another preference, not containing cell in described fat stem cell culture supernatant.
Fat pluripotent cell component
Fat pluripotent cell treatment osteoarthritis is appeared in the newspapers, obtains pluripotent cell from fat, more easy compared to traditional method, and source is wide, and in fat, the pluripotent cell content of tool CFU-F Forming ability is high, and multiplication capacity is strong.
Stromal vascular fraction (SVF) has therapeutic effect to osteoarthritis, and stromal vascular fraction transplants 1-2 hour from being separated to, and low price, the risk in cell culture can also be reduced, pluripotent cell simultaneously containing CD34+CD31-and CD34+CD31+ in stromal vascular fraction, has stronger promotion revascularization ability.In the present invention, described fat pluripotent cell can be primary fat pluripotent cell or the fat pluripotent cell that goes down to posterity.
In the present invention, by stromal vascular fraction and purification or cultivate the fat pluripotent cell coupling of increasing, thus improve both respective defects above-mentioned, improve revascularization ability, improve effect more obvious.
Preferably, the surface marker that described fat pluripotent cell is expressed is selected from lower group: CD90, CD34, CD10, CD36, CDCD45, CD105, CD29, CD44, CD49b, CD49e, CD58, HLA-ABC, CD73, CD13, CD63, CD166, CD31, CD106, CD71, or its combination.
The source of described fat pluripotent cell component is not particularly limited, and can be autologous fat pluripotent cell component or allosome fat pluripotent cell component.
Described fat pluripotent cell can be prefabricated or existing system, as, can before the treatment or extracting in treatment subject in treatment and carry out purification or cultivate amplification, also can making a commercial reagents by the fat pluripotent cell of xenogenic origin, for treating.
The compositions for the treatment of osteoarthritis
The invention provides one and treat the arthritic compositions of animal bone, it is characterized in that, comprise following component:
A. fat pluripotent cell component; And/or
Cartilage precursor cells component;
B. timbering material; With
C. pharmaceutically acceptable carrier.
In another preference, described compositions is fluid composition.
In another preference, described compositions is injection.
In another preference, described pharmaceutically acceptable carrier is injection carrier.
In another preference, described osteoarthritis is selected from lower group: knee osteoarthritis, hipbone arthritis, anklebone arthritis.
In another preference, described fat pluripotent cell component is autologous fat pluripotent cell component or allosome fat pluripotent cell component.
In another preference, described fat pluripotent cell component is selected from lower group: the fat pluripotent cell of purification, the fat pluripotent cell through cultivation amplification from stromal vascular fraction, or its combination.
In another preference, the described fat pluripotent cell through cultivating amplification be serum-free medium or containing the culture medium of serum in carry out increasing.
In another preference, described fat pluripotent cell component is the standby or cryopreservation resuscitation of immediate system.
In another preference, except fat pluripotent cell, described fat pluripotent cell component also can containing the cell being selected from lower group: adipose cell, endotheliocyte, smooth muscle cell, pericyte, fibroblast, mastocyte, neurocyte, Preadipocyte, lymphocyte, blood cell, stromal cell, macrophage, or its combination.
In another preference, in described fat pluripotent cell component, fat pluripotent cell quantity accounts for 0.5 ~ 100% of total cell quantity, is preferably 1 ~ 100%, is more preferably 10 ~ 100%.
In another preference, described fat pluripotent cell component is autologous or allochthonous.
In another preference, described fat pluripotent cell component has cartilage differentiation potential.
In another preference, also containing cytokine in described fat pluripotent cell component.
In another preference, described cytokine is selected from lower group: TGF-β, PDGF, VEGF, IL-1, IL-6, TNF, IRAP, CTGF, EGF, IGF, BFGF, or its combination.
In another preference, described fat pluripotent cell concentration is in the composition 1 × 10
3-5 × 10
8/ mL is preferably 1 × 10
4-1 × 10
8/ mL is more preferably 1 × 10
5-1 × 10
7/ mL.
In another preference, described fat pluripotent cell component is CD45-CD235a-CD31-CD34+ cell, and/or the fat pluripotent cell component of CD45-CD13+CD36+CD73+ cell enrichment.
In another preference, described CD45-CD235a-CD31-CD34+ cell and/or CD45-CD13+CD36+CD73+ cell enrichment refer to that the content of described CD45-CD235a-CD31-CD34+ cell and/or CD45-CD13+CD36+CD73+ cell accounts for the 15-100% of cell total amount in component.
In another preference, described " CD45-CD235a-CD31-CD34+ " cell refers to containing CD34 cytokine not containing CD45, CD235a and CD31 cytokine.
Described compositions can also comprise other compositions, is selected from one or more compositions of lower group as comprised:
Be rich in hematoblastic blood plasma (PRP) and/or fat stem cell culture supernatant;
Vitamin B12;
Vitamin C; With
Anti-inflammatory drug.
In another preference, the described hematoblastic blood plasma (PRP) that is rich in is selected from lower group: the PRP after activation, does not activate PRP liquid, PRP gel, or its combination.
In another preference, described in be rich in hematoblastic blood plasma, PC scope is 0.5 × 10
6-1.5 × 10
10/ mL, and in described blood plasma, leukocyte and erythrocytic total concentration are≤1 × 10
6/ mL.
In another preference, described in be rich in hematoblastic blood plasma, PC scope is 5 × 10
7-5 × 10
8/ mL.
In another preference, containing cytokine in described fat stem cell culture supernatant.
In another preference, containing the cytokine being selected from lower group: TGF-β, HGF, IGF-1, VEGF, TGF-1, PDGF, VEGF, EGF, IGF, BFGF in described fat stem cell culture supernatant, or its combination.
In another preference, described fat stem cell culture supernatant is the fat stem cell culture supernatant of deactivation.
In another preference, not containing cell in described fat stem cell culture supernatant.
In the present invention, preferred described timbering material is selected from lower group: hyaluronic acid sodium, collagen protein, polysaccharide, or its combination.
In another preference, described polysaccharide is selected from lower group: hyaluronic acid, derivatives of hyaluronic acids, dextran, alginic acid, chitin, or its combination.
In another preference, described timbering material is the combination of hyaluronic acid sodium and collagen protein.
In another preference, described hyaluronic acid sodium and collagen protein first carry out premixing, then mix with other materials.
In the present invention, preferred described anti-inflammatory drug is selected from lower group: glucocorticoid AID, meloxicam, Luo Beikao former times, or its combination.
In another preference, described in be rich in hematoblastic blood plasma and/or fat stem cell culture supernatant gross weight in the composition than being 5-95 weight portion, with the total weight of compositions.
In another preference, described timbering material weight ratio is in the composition 5-95 weight portion, is preferably 10-90 weight portion, with the total weight of compositions.
In another preference, the weight ratio of described vitamin B12 is 0.01-10 weight portion, with the total weight of compositions.
In another preference, the weight ratio of described anti-inflammatory drug is 10-95 weight portion, with the total weight of compositions.
In another preference, in described compositions, the gross weight ratio of described fat pluripotent cell component and/or cartilage precursor cells component is 0.1-10 weight portion, with the total weight of compositions.
In another preference, in described compositions, described ascorbic weight ratio is 0.01-10 weight portion, with the total weight of compositions.
In the present invention, described animal species is not particularly limited, and is preferably mammal, is more preferably selected from lower group: primate, Canis animals, equine species, rabbit section animal.
Described compositions can be prepared into dosage form, as injection, injection etc., for injecting the diseased joints for the treatment of target.
In a preferred embodiment of the invention, in described preparation,
The concentration of described fat pluripotent cell is 10
4-10
7/ mL;
Hematoblastic concentration is 5 × 10
7-5 × 10
8/ mL;
Leukocytic concentration is≤5 × 10
5mL;
Erythrocytic concentration is≤5 × 10
5mL; And
The volume of described preparation is 0.1-15mL; And
The somatomedin being selected from lower group is also comprised: TGF-β, PDGF, VEGF, IL-1, IL-6, TNF, IRAP, CTGF, EGF, IGF, BFGF in described blood plasma, or its combination; And/or
The somatomedin being selected from lower group is also comprised: TGF-β, HGF, IL-10, TGF-1, PDGF, VEGF, EGF, IGF, BFGF in described fat stem cell culture supernatant, or its combination; And/or
Also cytokine is comprised in described fat pluripotent cell component, and described cytokine is selected from lower group: TGF-β, TIMPs, VEGF, HGF, PGE2, IGF-1, MIP-1a, IL-6, IDO, GM-CSF, IL-1RA, IL-12p40, IL-10, IL-13, or its combination; And/or
Also cytokine is comprised in described cartilage precursor cells component, and described cytokine is selected from lower group: TGF-β, TIMPs, VEGF, HGF, PGE2, IGF-1, MIP-1a, IL-6, IDO, GM-CSF, IL-1RA, IL-12p40, IL-10, IL-13, or its combination; And/or
The surface marker that described fat pluripotent cell component is expressed is selected from lower group: CD90, CD34, CD10, CD36, CDCD45, CD105, CD29, CD44, CD49b, CD49e, CD58, HLA-ABC, CD73, CD13, CD63, CD166, CD31, CD106, CD71, or its combination.
Preferably, the volume of described preparation can according to the volume of disease sites, factors such as coincident with severity degree of condition and changing, and as in the middle of a preference of the present invention, the kneed preparation amount of application of large-scale dog is 1-3mL; In another preference, the amount of application of horse racing hip joint is 10-15ml.
Pharmaceutically acceptable carrier
In the present invention, can by the mixture of compositions and pharmaceutically acceptable excipient, diluent etc. with non-oral mode, as the form administration of injection.This pharmaceutical composition preferably containing weight ratio be the compositions of the present invention of 0.01%-99% as active component, more preferably containing weight ratio be the active component of 0.1%-90%.
Above-mentioned preparation is prepared by conventional pharmaceutical method.The example of available medicinal adjuvant comprises diluent and injection solvent (such as water, ethanol and glycerol etc.).
Major advantage of the present invention comprises:
1. the present invention adopts timbering material and fat stem cell component to combine mutually, thus extends the time that effective ingredient retains at diseased region, enhances therapeutic effect.
2. preparation of the present invention can retain the moisture in affected part, cell and other effective ingredient effectively, has better therapeutic effect.
3. preparation of the present invention with the addition of anti-inflammatory drug, thus can slow down treatment target arthralgia while treatment.
4. preparation of the present invention with the addition of vitamin ingredients, effectively can improve the growth of cartilage.
5. compare prior art, the volume injected needed for preparation of the present invention is less, can not cause burden after injection to patient articular, has better therapeutic effect.
Below in conjunction with specific embodiment, set forth the present invention further.Should be understood that these embodiments are only not used in for illustration of the present invention to limit the scope of the invention.The experimental technique of unreceipted actual conditions in the following example, usually conveniently condition, or according to the condition that manufacturer advises.Unless otherwise indicated, otherwise percentage ratio and number calculate by weight.
Embodiment 1:
The biological product of preparation treatment osteoarthritis
One, from fatty tissue fractionation of fatty pluripotent cell component
1. isolation medium vascular components
Extract fatty tissue 30-50ml from patient for fat portion, fatty tissue is minute centrifugal through 800g × 5, get centrifugal after upper-layer fat digest 45 minutes with the PBS containing 0.075% collagenase, centrifugal, abandon upper liquid, the cell precipitation of DMEM resuspended lower floor mixing.Cyclic washing removes collagenase 3 times.Collect aspirated liquid 500ml, 800g × 5 are minute centrifugal, and abandon upper liquid, piping and druming, adds normal saline 200ml and shake 30 seconds simultaneously, add 22.2ml10 × PBS and recover to wait, centrifugal, resuspended, totally 3 times.Two parts re-suspension liquid mixed, 100 mesh filter screens filter.Use blood counting chamber to measure cell concentration, be centrifugally resuspended in DMEM, adjustment cell concentration is 3 × 10
7individual/ML.
2. the fat pluripotent cell in separation and purification vascular stroma composition
The vascular stroma component cells be separated is resuspended in FACS buffer (PBS containing 1%BSA and 0.05% Hydrazoic acid,sodium salt), adjustment cell to 10
5individual cell, adds antibody, hatches on ice after mixing.According to express cell surface markers level, use FACSvantage
tM(Becton Dickinson) sorting CD45-CD235a-CD31-CD34+ cell and CD34+CD31+ cell.Adding DMEM adjustment cell concentration is 3 × 10
7individual/ML.
3. cultivate amplification fat pluripotent cell
By the stromal vascular fraction cell centrifugation obtained, be resuspended in serum-free medium, adjustment cell concentration to 3 × 10
5individual/cm
2, be seeded in T75 culture bottle and cultivate, after cell proliferation to degrees of fusion reaches 80%, carry out passage.When P3 is for cell fusion to 80%, uses trypsin digestion and cell, be resuspended in DMEM after centrifugal, adjustment cell concentration is 3 × 10
7individual/ML.
4. mixing is several containing pluripotent cell composition
Get vascular stroma component cells 0.5ML, the fat pluripotent cell 0.5ML of purification and the fat pluripotent cell 0.5ML of cultivation to mix in centrifuge tube, altogether 1.5ML.Flow cytometer detection mixed liquor CD45-CD235a-CD31-CD34+ and CD45-CD13+CD36+CD73+ pluripotent cell content, pluripotent cell final concentration is 2.1 × 10
7individual/ML.
5. streaming surface marker measures
Get mixed pluripotent cell sample, by 5 × 10
6cell to put into 1.5ml centrifuge tube 3000r/ minute centrifugal 5 minutes, abandon supernatant.Add FACS buffer 100 microlitre suspension cell.Add closing cell's surface Fc receptors 0.5 microlitre (0.5mg/ml), water-bath 3 minutes.Add fluorescent antibody 1 microlitre (0.5mg/ml), water-bath 30 minutes.Add FACS buffer 350 microlitre, mix gently, 3000r/ minute, centrifugal 5 minutes, abandon supernatant, repeated washing 2 times.Getting 100 microlitre l buffering instrument liquid adds in the cell precipitation of acquisition, mixes suspension cell gently, is moved into by cell suspension in FACS dedicated pipe, BD flow cytometer carries out instrument determination and analysis.
Detect mixing pluripotent cell express surface marker be: CD90, CD34, CD10, CD36, CD45, CD73, CD13, CD31, CD106, CD71, the surface marker of not expressing is: CD133, CD14, CD79 α, CD19, HLA-DR.
6. cartilage differentiation ability detects
Get mixed pluripotent cell sample and be seeded to 24 orifice plates, merge to 80%, be replaced with chondrocyte induction liquid (10ng/mL TGF, 10mmol/mL dexamethasone, 50mg/mL vitamin C, DMEM in high glucose are mixed with), within every 3 days, change liquid 1 time, induce 11 days, matched group uses.Coverslip is placed in advance in culture hole during inducing culture, make cell paste coverslip growth, take out cell climbing sheet to when 11 days, volume fraction 10% formaldehyde fixes 1 hour, PBS rinses 15 minutes, distilled water flushing 1 time, drips the dyeing of 10g/L Ah Xinlan, dyes 3 hours, add 95% ethanol, wash away unnecessary dye liquor, dry, neutral gum mounting.
Detect pluripotent cell can be divided into chondrocyte, matched group Analytical Chemical Experiment result is negative.
Two, hematoblastic blood plasma is rich in separation
Extract patient 20ML peripheral blood, shake up, insert in centrifuge tube, carry out two times centrifugal.Centrifugal speed 1500 revs/min for the first time, from 10 minutes.Be divided into the erythrocyte of the blood plasma on upper strata and lower floor two-layer after centrifugal.Discard the erythrocyte being positioned at centrifuge tube bottom, draw whole blood plasma to another centrifuge tube.Use filter for removing white blood cell filtered plasma, remove leukocyte.The blood plasma of filtration is carried out second time centrifugal, speed 3000 revs/min, centrifugal 10 minutes, what blood plasma was divided into the platelet-poor plasma on upper strata and lower floor is rich in hematoblastic blood plasma, takes off layer and is rich in hematoblastic blood plasma.
What adopt pocH-100i cellanalyzer (Japanese Sysmex company) detection to be separated is rich in platelet content 9.7 × 10 in platelet
7individual/ML, leucocyte content 1.1 × 10
5individual/ML, red blood cell content 4.3 × 10
5individual/ML.
Three, ELISA detects pluripotent cell culture supernatant and is rich in cytokine-expressing in hematoblastic blood plasma
Get mixed pluripotent cell sample by 10
5individual/cm2 is seeded in culture dish, and adhere-wall culture got culture supernatant after 36 hours, detects TGF-β, HGF, IGF-1, vegf expression by ELISA method.
Plateletrich blood plasma adds activator (500U thrombin lyophilized powder be dissolved in 1mL10% calcium chloride) by volume at 1: 9, activate platelet rich plasma, room temperature left standstill after 24 hours, 4000 revs/min, within centrifugal 15 minutes, extract extract, detect the expression of cytokine by ELISA method.
Testing result shows: pluripotent cell culture supernatant expresses TGF-β, HGF, IGF-1, VEGF, is rich in cytokine-expressing TGF-β, PDGF, VEGF, EGF, IGF, BFGF in hematoblastic blood plasma.
Four, mix pluripotent cell component, be rich in hematoblastic blood plasma, hyaluronic acid, buffer
Separately preserve before using, pluripotent cell component 1.5ML, PRP0.5ML during use, hyaluronic acid 0.5ML, the calcium chloride buffer 0.5ML of 10%.3ML, adds rear slight oscillatory 5 minutes altogether.
Five, the cryopreservation resuscitation of biological product
In biological product, pluripotent stem cell component adds 10%DMSO, lowers the temperature in programmed cooling instrument, is stored in-196 DEG C of liquid nitrogen, during use in 37 DEG C of water-baths rapid fluid resuscitation, recovery after Cell viability >90%.Be rich in the DMSO that hematoblastic blood plasma adds 5%, put into-80 DEG C of refrigerators and preserve, room temperature rewarming during use.Hyaluronic acid and 10% calcium chloride buffer preserve in 4 degrees Celsius, room temperature rewarming during use.
Embodiment 2:
The preparation of biological product and be used for the treatment of the arthritic experiment of Os Leporis seu Oryctolagi
One, biological product preparation:
1) fatty 10ML under separation rabbit skin, uses enzyme digestion to obtain stromal vascular fraction, and adjustment cell concentration is 1 × 10
7individual/ML.Cultivate the fat pluripotent cell of amplification, adjustment cell concentration is 1 × 10
7individual/ML.Get the fat pluripotent cell mixing of 0.1ML stromal vascular fraction and 0.1ML amplification, flow cytometer detection mixed liquor CD45-CD235a-CD31-CD34+ and CD45-CD13+CD36+CD73+ pluripotent cell content.Pluripotent cell final concentration is 6.5 × 10
6individual/ML.
2) extract rabbit femoral artery blood 10ML, for the first time centrifugal speed 1500 revs/min, centrifugal 10 minutes, draw upper plasma to another centrifuge tube.Hematoblastic blood plasma is rich in centrifugalize, each speed 3000 revs/min, centrifugal 10 minutes, removes upper strata containing leukocyte and erythrocyte liquid, takes off layer and be rich in hematoblastic blood plasma, be resuspended in normal saline, repeated centrifugation 3 times.PocH-100i cellanalyzer (Japanese Sysmex company) is adopted to detect platelet content 5 × 10 in the Platelet-rich plasm be separated
7individual/ML, leucocyte content 5 × 10
4individual/ML, red blood cell content 1.2 × 10
5individual/ML.
3) get fat pluripotent cell component 0.2ML, be rich in hematoblastic blood plasma 0.05ML, hyaluronic acid 0.04ML, the calcium chloride buffer 0.01ML of 10%, after slight oscillatory mixing, be total to 0.3ML.
Two, Os Leporis seu Oryctolagi arthritis modeling
Select healthy adult New Zealand large ear rabbit, body weight 4 to 5 kilograms.Rabbit rear left knee joint is carried out anterior cruciate ligament-transection art and combines modeling with medial meniscus excision, right knee joint side in contrast, after performing the operation 6 weeks, pathological evaluation osteoarthritis modeling effect.
Three, Os Leporis seu Oryctolagi arthritis treatment
Latter 4th week of evaluation modeling success, use syringe to the joint injection 0.3ml biological product of suffering from osteoarthritis under ultrasound guidance, slowly inject.
Four, treatment effectiveness evaluation
Latter 10th week of acceptance treatment, detect:
1) joint pathology is observed
Joint is fixed with 10% formaldehyde, after sample decalcification, is cut into slices after paraffin embedding, carry out HE dyeing after removing distal femoral and tibial plateau.As shown in Figure 1, Normal Knee cartilage top layer is intact, and chondrocyte is normal for result; The untreated knee cartilage top layer of matched group is obviously destroyed, and peeling-off phenomenon is obvious, top layer cartilage cavity sample degeneration, ripe chondrocyte column heading line off, and structural deterioration is obvious; Cartilage after cell therapy, the cartilage top layer of destruction recovers intact, and the degeneration of cavity sample does not normally occur cartilage, and ripe chondrocyte column line recovers.
2) Mankin scoring
Joint is fixed with 10% formaldehyde, after sample decalcification, is cut into slices after paraffin embedding after removing distal femoral and tibial plateau, carries out HE dyeing, toluidine blue and safranin O dyeing.Adopt Mankin point system to mark to joint, result is as shown in table 1.
Table 1Mankin appraisal result
| Normal group | Treatment group | Model control group |
| 0.3 | 1.5 | 5.5 |
3) get joint fluid, adopt ELISA method to detect the inflammatory factors such as TNF-α, IL-6, MMP-13 and express.In treatment posterior joint liquid, TNF-alpha content detects as shown in table 2.
Table 2ELISA method testing result
| Normal group | Treatment group | Model control group | |
| 1st day | 30 | 30 | 30 |
| 20th day | 30 | 100 | 100 |
| 40th day | 30 | 35 | 105 |
4) magnetic Resonance Imaging MRI observation is carried out in rabbit joint, detect joint recovery and cartilage volume.Treat articular cartilage of immobilized total amount change in 10 weeks as shown in table 3.
Table 3 cartilage content
| Normal group | Treatment group | Model control group |
| 10 | 9 | 4 |
Embodiment 3:
The preparation of biological product and the treatment for Human Osteoarthritis
One, biological product preparation:
1) be separated patient's subcutaneous fat 30ML, use enzyme digestion to obtain stromal vascular fraction, inoculation stromal vascular fraction is to T75 culture bottle, and amplification cultivation fat pluripotent cell, grows to degrees of fusion 80%, and enzymic digestion obtains cell, and adjustment cell concentration is 5 × 10
7individual/ML.Get the fat pluripotent cell mixing of 0.1ML stromal vascular fraction and 0.1ML amplification, CD45-CD235a-CD31-CD34+ and CD45-CD13+CD36+CD73+ pluripotent cell content in flow cytometer detection mixed liquor.Pluripotent cell final concentration is 4.97 × 10
7individual/ML.
2) extract human peripheral 20ML, first time centrifugal speed 1500r/min, centrifugal 10 minutes, draw upper plasma to another centrifuge tube.Hematoblastic blood plasma is rich in centrifugalize, each speed 3000r/min, centrifugal 10 minutes, removes upper strata containing leukocyte and erythrocyte liquid, takes off layer and be rich in hematoblastic blood plasma, be resuspended in normal saline, repeated centrifugation 3 times.PocH-100i cellanalyzer (Japanese Sysmex company) is adopted to detect platelet content 5 × 10 in the Platelet-rich plasm be separated
8individual/ML, leucocyte content 9 × 10
4individual/ML, red blood cell content 4 × 10
5individual/ML.
3) get fat pluripotent cell component 1ML, be rich in hematoblastic blood plasma 1ML, after the mixing of hyaluronic acid 1ML slight oscillatory, be total to 3ML.
Two, biological product are used for the treatment of Patients with Knee Osteoarthritis
Patients with Knee Osteoarthritis 20, is divided into 2 groups.Organize 1 patient and slowly inject 3ml biological product under ultrasound guidance to the articular cavity of suffering from osteoarthritis; Organize 2 patients and accept the biological product hyaluronic acid increase volume of injection to 8ML, be slowly expelled to the joint of suffering from osteoarthritis under ultrasound guidance.Postoperatively to follow up a case by regular visits at 2,5,10,18,52 weeks.
Three, treatment effectiveness evaluation
Biological product are expelled in the articular cavity of osteoarthritis, and the biological product of 3ml volume are in injection process, and the swollen sense of acid of patient's reflection and pain are lower than the biological product of 8ml volume.
1. pain in knee osteoarthritis alleviates scoring
Pain relief scores is as shown in table 4, and remission scoring is as shown in table 5.
Table 4 pain relief scores
| 3ml | 8ml | |
| 0th week | 35 | 35 |
| 2nd week | 39 | 37 |
| 5th week | 45 | 43 |
| 10th week | 48 | 46 |
| 18th week | 50 | 47 |
| 52nd week | 51 | 48 |
Table 5 remission is marked
| 3ml | 8ml | |
| 0th week | 31 | 31 |
| 2nd week | 36 | 35 |
| 5th week | 39 | 34 |
| 10th week | 41 | 38 |
| 18th week | 43 | 40 |
| 52nd week | 47 | 44 |
Result shows, and volume is the biological product of 3ml are better than volume 8ml biological product to pain and remission effect.
2. ultrasonic mensuration cartilage thickness (mm, n=10)
The ultrasonic mensuration cartilage thickness of table 6.
Ultrasonic measurement result display, volume is that the biological product cartilage recovery effects of 3ml is better than the biological product that volume is 8ml.
Embodiment 4:
Be rich in hematoblastic blood plasma adopt remove leukocyte and erythrocyte operation after for osteoarthritis treatment
One, be rich in hematoblastic blood plasma be separated and reduce leukocyte and red blood cell content operation
Extract Canine femoral artery blood 12ML, first time centrifugal speed 1500r/min, centrifugal 10 minutes, draw upper plasma to another centrifuge tube.Use filter for removing white blood cell filtered plasma, remove leukocyte.Hematoblastic blood plasma is rich in centrifugalize, each speed 3000r/min, centrifugal 10 minutes, removes upper strata containing leukocyte and erythrocyte liquid, takes off layer and be rich in hematoblastic blood plasma, be resuspended in normal saline, repeated centrifugation 3 times.PocH-100i cellanalyzer (Japanese Sysmex company) is adopted to detect platelet content 3 × 10 in the Platelet-rich plasm be separated
8individual/ML, leucocyte content 3 × 10
3individual/ML, red blood cell content 7 × 10
4individual/ML.
Do not carry out remove erythrocyte and leukocyte operation be rich in platelet content 2.8 × 10 in hematoblastic blood plasma
8individual/ML, leucocyte content 1 × 10
6individual/ML, red blood cell content 5 × 10
6individual/ML.
Two, the treatment of hematoblastic blood plasma for Os Canitis arthritic is rich in
Canis familiaris L. rear left knee joint is carried out anterior cruciate ligament-transection art and is combined modeling with medial meniscus excision.The model Canis familiaris L. suffering from osteoarthritis is divided into two groups, often organizes 10.The Canis familiaris L. of group 1 is slowly injected 0.5ml under ultrasound guidance and removes erythrocyte and be leukocyticly rich in hematoblastic blood plasma to osteoarthritic joint; The Canis familiaris L. of group 2 is slowly injected 0.5ml under ultrasound guidance and is not removed erythrocyte and be leukocyticly rich in hematoblastic blood plasma to osteoarthritic joint, postoperatively follows up a case by regular visits at 30,60 and 90 days.
Three, treatment effectiveness evaluation
1. TOP SCORES
Test and assess to limpings after Canis familiaris L. treatment, limitation of activity, dysfunction, result display, the overall state for the treatment of group comparatively matched group has clear improvement (overall score).Wherein, limping situation is improved obviously, and obviously improving (P<0.05) namely appears after 30 days in the limping in walking, occurs improving and continuing to 90 days further to 60 days; And the limping in jumping improves more obvious, within about 30 days, namely occur significantly improving (P<0.01), and be retained to about 90 days always.The mobility in joint is improved also quite obvious, within about 30 days, just occurs significantly improving (P<0.01), and one until experiment terminates all for occurring repeatedly.The TOP SCORES for the treatment of group and matched group compared, result is as shown in table 7.
Table 7ELISA method testing result
| PRP | PRP－WBC－RBC | |
| 30th day | 19 | 29 |
| 60th day | 25 | 39 |
| 90th day | 27 | 37 |
Biological product conposition provided by the invention is in transplantation treatment osteoarthritis and zoopery treatment, and cartilage has obvious recovery, significantly variant compared with matched group, and recovery situation is close with normal group.Treatment group new vessels situation is better than matched group; Treatment posterior joint liquid inflammatory factor is significantly lowered, with normal value without significant difference.Clinical patient receives treatment, and pain sense of discomfort is weak, and knee joint function recovers good, and scoring is significantly higher than matched group.Result shows, and compositions provided by the invention effectively can treat osteoarthritis.
The all documents mentioned in the present invention are quoted as a reference all in this application, are just quoted separately as a reference as each section of document.In addition should be understood that those skilled in the art can make various changes or modifications the present invention after having read above-mentioned teachings of the present invention, these equivalent form of values fall within the application's appended claims limited range equally.
Claims (10)
1. treat the arthritic compositions of animal bone, it is characterized in that, comprise following component:
A. fat pluripotent cell component; And/or
Cartilage precursor cells component;
B. timbering material; With
C. pharmaceutically acceptable carrier.
2. compositions as claimed in claim 1, it is characterized in that, described compositions also comprises one or more compositions being selected from lower group:
Optional is rich in hematoblastic blood plasma (PRP) and/or fat stem cell culture supernatant;
Vitamin B12;
Vitamin C; With
Anti-inflammatory drug.
3. compositions as claimed in claim 1, it is characterized in that, described timbering material is selected from lower group: hyaluronic acid sodium, collagen protein, polysaccharide, or its combination.
4. compositions as claimed in claim 1, it is characterized in that, described anti-inflammatory drug is selected from lower group: glucocorticoid AID, meloxicam, Luo Beikao former times, or its combination.
5. compositions as claimed in claim 1, is characterized in that, described fat pluripotent cell component and/or cartilage precursor cells component gross weight ratio is in the composition 5-95 weight portion, with the total weight of compositions; And/or
Described timbering material weight ratio is in the composition 5-95 weight portion, is preferably 10-90 weight portion, with the total weight of compositions.
6. the compositions as described in as arbitrary in claim 1-5, it is characterized in that, described animal is selected from lower group: primate, Canis animals, equine species, rabbit section animal.
7. the method for making of compositions as described in as arbitrary in claim 1-6, it is characterized in that, described method comprises step: each component mixed, make compositions.
8. be used for the treatment of the arthritic preparation of animal bone, it is characterized in that, described preparation comprise as arbitrary in claim 1-6 as described in compositions as effective ingredient.
9. preparation as claimed in claim 8, is characterized in that, in described preparation,
The concentration of described fat pluripotent cell is 10
4-10
8/ mL;
Hematoblastic concentration is 5 × 10
7-5 × 10
8/ mL;
Leukocytic concentration is≤5 × 10
5mL;
Erythrocytic concentration is≤5 × 10
5mL; And
The volume of described preparation is 0.1-15mL; And
The somatomedin being selected from lower group is also comprised: TGF-β, PDGF, VEGF, IL-1, IL-6, TNF, IRAP, CTGF, EGF, IGF, BFGF in described blood plasma, or its combination; And/or
The somatomedin being selected from lower group is also comprised: TGF-β, HGF, IL-10, TGF-1, PDGF, VEGF, EGF, IGF, BFGF in described fat stem cell culture supernatant, or its combination; And/or
Also cytokine is comprised in described fat pluripotent cell component and/or described cartilage precursor cells component, and described cytokine is selected from lower group: TGF-β, TIMPs, VEGF, HGF, PGE2, IGF-1, MIP-1a, IL-6, IDO, GM-CSF, IL-1RA, IL-12p40, IL-10, IL-13, or its combination; And/or
The surface marker that described fat pluripotent cell component is expressed is selected from lower group: CD90, CD34, CD10, CD36, CDCD45, CD105, CD29, CD44, CD49b, CD49e, CD58, HLA-ABC, CD73, CD13, CD63, CD166, CD31, CD106, CD71, or its combination.
10. treat the arthritic agent combination of animal bone or a test kit, it is characterized in that, comprise the reagent of description and lower group:
A. fat pluripotent cell component; And/or
Cartilage precursor cells component;
B. timbering material;
And describe operational version in described description;
Preferably, one or more components being selected from lower group are also comprised in described test kit: be rich in hematoblastic blood plasma (PRP), fat stem cell culture supernatant, vitamin B12, vitamin C; And anti-inflammatory drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310688816.3A CN104706675A (en) | 2013-12-13 | 2013-12-13 | Composition for treating osteoarthritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310688816.3A CN104706675A (en) | 2013-12-13 | 2013-12-13 | Composition for treating osteoarthritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104706675A true CN104706675A (en) | 2015-06-17 |
Family
ID=53406720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310688816.3A Withdrawn CN104706675A (en) | 2013-12-13 | 2013-12-13 | Composition for treating osteoarthritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104706675A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108324992A (en) * | 2017-01-19 | 2018-07-27 | 国玺干细胞应用技术股份有限公司 | Composition for cartilage repair and method for repairing articular cartilage |
| CN114225017A (en) * | 2021-12-30 | 2022-03-25 | 武汉冉谷医疗有限公司 | Composition for treating osteoarthritis or repairing cartilage damage and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103340904A (en) * | 2013-07-10 | 2013-10-09 | 西比曼生物科技（上海）有限公司 | Composition for treating osteoarthritis |
-
2013
- 2013-12-13 CN CN201310688816.3A patent/CN104706675A/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103340904A (en) * | 2013-07-10 | 2013-10-09 | 西比曼生物科技（上海）有限公司 | Composition for treating osteoarthritis |
Non-Patent Citations (1)
| Title |
|---|
| 张安祯: "《中医骨伤科学》", 30 April 2007 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108324992A (en) * | 2017-01-19 | 2018-07-27 | 国玺干细胞应用技术股份有限公司 | Composition for cartilage repair and method for repairing articular cartilage |
| CN114225017A (en) * | 2021-12-30 | 2022-03-25 | 武汉冉谷医疗有限公司 | Composition for treating osteoarthritis or repairing cartilage damage and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103340904B (en) | The compositions for the treatment of osteoarthritis | |
| CN104707140A (en) | Composition for treating osteoarthritis | |
| CN108671224A (en) | Composition, purposes and the preparation of platelet cracking content | |
| CN104704111A (en) | Isolation of stem cells from adipose tissue by ultrasonic cavitation, and methods of use | |
| CN105154395A (en) | Preparing method for clinic level cells for enhancing immune modulating function of MSCs | |
| KR20140040696A (en) | Cell therapy composition for preventing or treating immune disease comprising mesenchymal stem cell and regulatory t cell | |
| CN111849882A (en) | Mesenchymal stem cell exosome and preparation method and application thereof | |
| CN108865986A (en) | For repairing articular cartilage damage/defect mescenchymal stem cell preparation and its preparation method and application | |
| AU2013206755B2 (en) | Activating adipose-derived stem cells for transplantation | |
| Monteiro et al. | Biologic strategies for intra-articular treatment and cartilage repair | |
| CN110935010A (en) | Stem cell preparation, growth factor composition, preparation method and application thereof | |
| CN116474000B (en) | Umbilical cord mesenchymal stem cell preparation, preparation method and application thereof in treating knee osteoarthritis | |
| CN104706675A (en) | Composition for treating osteoarthritis | |
| CN104707141A (en) | Composition for treating osteoarthritis | |
| WO2014015229A1 (en) | Isolation of stromal vascular fraction from adipose tissue obtained from postmortem source using ultrasonic cavitation | |
| CN115381856A (en) | Application of adipose-derived mesenchymal stem cells in preparation of medicine or preparation for treating knee osteoarthritis | |
| CN105112367B (en) | A kind of mescenchymal stem cell epidermal differentiation derivant and its application process | |
| CN106110302A (en) | The stem cell medicine for the treatment of diabetic foot | |
| CN110402286B (en) | Method for preparing mesenchymal stem cell population from peripheral blood and application thereof | |
| EP3070164A1 (en) | System and method for providing isolated concentrated multipotent stromal cells for administration | |
| US20210077538A1 (en) | Methods and compositions for treatment of penile defects | |
| CN104707142A (en) | Kit for treating animal rheumatoid arthritis | |
| WO2015085957A1 (en) | Composition for treating osteoarthritis | |
| CN103816183A (en) | Application of stromal vascular fraction cells and mesenchymal progenitor cells to prevention or treatment of osteoarthritis | |
| AU2014211790B2 (en) | Use of allogeneic interstitial vessel-layer cell and allogeneic mesenchymal progenitor cell for preventing or treating osteoarthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20150617 |
|
| WW01 | Invention patent application withdrawn after publication |